Dermagnostix Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 42

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 14

Dermagnostix General Information

Description

Developer of molecular diagnostic tests designed to differentiate inflammatory skin diseases. The company offers a comprehensive technology platform that helps in fast and objective diagnostics and helps to differentiate between eczema and psoriasis on a molecular level, enabling dermatologists and dermatopathologists to achieve precise diagnoses and make informed treatment decisions.

Contact Information

Website
www.dermagnostix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Engesserstraße 4a
  • 79108 Freiburg
  • Germany
+49 0761
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Digital Health, HealthTech
Corporate Office
  • Engesserstraße 4a
  • 79108 Freiburg
  • Germany
+49 0761

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dermagnostix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Accelerator/Incubator 12-Jun-2026 Completed Generating Revenue
8. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
7. Seed Round 22-Jul-2022 Completed Generating Revenue
6. Grant 22-Jul-2022 Completed Generating Revenue
5. Grant 23-Mar-2022 Completed Generating Revenue
4. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
3. Grant 17-Mar-2020 Completed Generating Revenue
2. Angel (individual) $3.42M $3.42M Completed Generating Revenue
1. University Spin-Out 01-Jan-2020 Completed Generating Revenue
To view Dermagnostix’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Dermagnostix Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Dermagnostix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026132260-A1 Adhesion-based skin sample collection Pending 19-Dec-2024
WO-2026074068-A1 Integration of a scrape sample into a cartridge system Pending 02-Oct-2024
WO-2026074088-A1 Sampling kit for collection, storage and transport of a tissue sample Pending 02-Oct-2024
EP-4753849-A1 Sample carrier for use in a rotation-based method for amplifying dna and/or for detecting nucleic acids Pending 03-Aug-2023
WO-2025027112-A1 Sample carrier for use in a rotation-based method for amplifying dna and/or for detecting nucleic acids Inactive 03-Aug-2023 B01L7/52
To view Dermagnostix’s complete patent history, request access »

Dermagnostix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dermagnostix Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
MedTech Innovator Accelerator/Incubator
German Accelerator Accelerator/Incubator
Ascenion Accelerator/Incubator Minority
Bayerische Patentallianz Corporation Minority
European Research Council Government Minority
You’re viewing 5 of 14 investors. Get the full list »

Dermagnostix Acquisitions (1)

Dermagnostix’s most recent deal was a Merger/Acquisition with Dialunox (Fluorescence Detector Technology). The deal was made on 01-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dialunox (Fluorescence Detector Technology) 01-May-2025 Merger/Acquisition Other Healthcare Technology Systems
To view Dermagnostix’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Dermagnostix FAQs

  • When was Dermagnostix founded?

    Dermagnostix was founded in 2020.

  • Where is Dermagnostix headquartered?

    Dermagnostix is headquartered in Freiburg, Germany.

  • What is the size of Dermagnostix?

    Dermagnostix has 42 total employees.

  • What industry is Dermagnostix in?

    Dermagnostix’s primary industry is Diagnostic Equipment.

  • Is Dermagnostix a private or public company?

    Dermagnostix is a Private company.

  • What is Dermagnostix’s current revenue?

    The current revenue for Dermagnostix is .

  • How much funding has Dermagnostix raised over time?

    Dermagnostix has raised $8.78M.

  • Who are Dermagnostix’s investors?

    MedTech Innovator, German Accelerator, Ascenion, Bayerische Patentallianz, and European Research Council are 5 of 14 investors who have invested in Dermagnostix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process